New hope for rare blood cancers: fedratinib shows promise in early trial
NCT ID NCT05177211
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Frailty check may steer safer cancer care for seniors
- Can a different immune drug cut viral infections after stem cell transplants?
- Can a new drug reduce bloodletting for polycythemia vera?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a modified interferon rein in early myelofibrosis?